for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover Nature Reviews Drug Discovery
  [SJR: 11.742]   [H-I: 235]   [344 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
   Published by NPG Homepage  [135 journals]
  • Impact of target interactions on small-molecule drug disposition: an
           overlooked area
    • Impact of target interactions on small-molecule drug disposition: an overlooked area

      Impact of target interactions on small-molecule drug disposition: an overlooked area, Published online: 23 February 2018; doi:10.1038/nrd.2018.26

      Impact of target interactions on small-molecule drug disposition: an overlooked areaImpact of target interactions on small-molecule drug disposition: an overlooked area, Published online: 2018-02-23; doi:10.1038/nrd.2018.262018-02-23
      DOI: 10.1038/nrd.2018.26
       
  • Unexplored therapeutic opportunities in the human genome
    • Unexplored therapeutic opportunities in the human genome

      Unexplored therapeutic opportunities in the human genome, Published online: 23 February 2018; doi:10.1038/nrd.2018.14

      In 2014, the Illuminating the Druggable Genome programme was launched to promote the exploration of currently understudied but potentially druggable proteins. This article discusses how the systematic collection and processing of a wide array of biological and chemical data as part of this programme has enabled the development of evidence-based criteria for tracking the target development level of human proteins, which indicates a substantial knowledge deficit for approximately two out of five proteins in the human proteome. It also highlights the nature of the unexplored therapeutic opportunities for major protein families.Unexplored therapeutic opportunities in the human genome, Published online: 2018-02-23; doi:10.1038/nrd.2018.142018-02-23
      DOI: 10.1038/nrd.2018.14
       
  • Cancer: New path to improving immunotherapy
    • Cancer: New path to improving immunotherapy

      Cancer: New path to improving immunotherapy, Published online: 16 February 2018; doi:10.1038/nrd.2018.22

      Cancer: New path to improving immunotherapyCancer: New path to improving immunotherapy, Published online: 2018-02-16; doi:10.1038/nrd.2018.222018-02-16
      DOI: 10.1038/nrd.2018.22
       
  • Cancer: Reset your circadian clock
    • Cancer: Reset your circadian clock

      Cancer: Reset your circadian clock, Published online: 16 February 2018; doi:10.1038/nrd.2018.24

      Cancer: Reset your circadian clockCancer: Reset your circadian clock, Published online: 2018-02-16; doi:10.1038/nrd.2018.242018-02-16
      DOI: 10.1038/nrd.2018.24
       
  • Oncologists tap the microbiome in bid to improve immunotherapy outcomes
    • Oncologists tap the microbiome in bid to improve immunotherapy outcomes

      Oncologists tap the microbiome in bid to improve immunotherapy outcomes, Published online: 16 February 2018; doi:10.1038/nrd.2018.19

      A pioneering Merck & Co.-funded study is set to explore the ability of the microbiome to boost immuno-oncology therapy outcomes, and other companies are quickly gearing up to enter this clinical space.Oncologists tap the microbiome in bid to improve immunotherapy outcomes, Published online: 2018-02-16; doi:10.1038/nrd.2018.192018-02-16
      DOI: 10.1038/nrd.2018.19
       
  • Cancer: Fibroblast subtype provides niche for cancer stem cells
    • Cancer: Fibroblast subtype provides niche for cancer stem cells

      Cancer: Fibroblast subtype provides niche for cancer stem cells, Published online: 16 February 2018; doi:10.1038/nrd.2018.23

      Cancer: Fibroblast subtype provides niche for cancer stem cellsCancer: Fibroblast subtype provides niche for cancer stem cells, Published online: 2018-02-16; doi:10.1038/nrd.2018.232018-02-16
      DOI: 10.1038/nrd.2018.23
       
  • Gene therapy: Reprogramming α-cells reverses diabetes
    • Gene therapy: Reprogramming α-cells reverses diabetes

      Gene therapy: Reprogramming α-cells reverses diabetes, Published online: 01 February 2018; doi:10.1038/nrd.2018.7

      Gene therapy: Reprogramming α-cells reverses diabetesGene therapy: Reprogramming α-cells reverses diabetes, Published online: 2018-02-01; doi:10.1038/nrd.2018.72018-02-01
      DOI: 10.1038/nrd.2018.7
       
  • Inflammation: Microbiome manipulation ameliorates colitis
    • Inflammation: Microbiome manipulation ameliorates colitis

      Inflammation: Microbiome manipulation ameliorates colitis, Published online: 01 February 2018; doi:10.1038/nrd.2018.9

      Inflammation: Microbiome manipulation ameliorates colitisInflammation: Microbiome manipulation ameliorates colitis, Published online: 2018-02-01; doi:10.1038/nrd.2018.92018-02-01
      DOI: 10.1038/nrd.2018.9
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.167.29.208
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-